NEWS

TRACT Therapeutics, Inc. Receives Orphan-Drug Designation for TRK-001 from the U.S. FDA

TRACT Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company

Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T Cells

SCIENTIFIC REPORTS, A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T Cells in Living Donor Kidney Transplants” April...

TRACT Therapeutics, Inc. Launches the TRACT CryoBanking Program™

TRACT Therapeutics, Inc. Launches the TRACT CryoBanking Program™ to Collect and Bank a Patient’s Immune Cells for Future Treatment...

Results of Phase 1 Trial of Treg Adoptive Cell Transfer (TRACT) in Kidney Transplant Recipients

Results of a Phase 1 Trial of Treg Adoptive Cell Transfer (TRACT) in De Novo Living Donor Kidney Transplant Recipients Download the...

TRACT Therapeutics, Inc. Received FDA Approval for a Phase 2 Trial

TRACT Therapeutics, Inc. Received FDA Approval for a Phase 2 Trial Using a Patient’s Immune Cells to Prevent Organ Rejection CHICAGO -...

American Transplant Congress June 12, 2016

Results of a Phase 1 Trial of Treg Adoptive Cell Transfer (TRACT) in de novo living donor kidney transplant recipients. Download the full...

TRACT Therapeutics, Inc. Completes Phase I Safety Trial

TRACT Therapeutics, Inc. Completes Phase I Safety Trial Using a Patient’s Immune Cells to Prevent Organ Rejection Safety Data Presented...

International Society for Cellular Therapy

International Society for Cellular Therapy, Miltenyi Biotec Corporate Symposium, May 27, 2015, Las Vegas, NV Ann LeFever, PhD to present...

TRACT Therapeutics, Inc. in White City News

“A kidney transplant that lasts for life. It’s the ultimate goal. But the drugs that keep a donor organ going also pose the greatest...